Introduction
Targeted expression of therapeutic genes to the angiogenic vasculature would provide a valuable treatment option for a number of disorders, such as ischemic heart disease, 1 diabetic retinopathy, 2 rheumatoid arthritis, 3 malignant tumors 4 and peripheral artery disease. 5 To date, a number of targeted gene-delivery strategies have been developed to express therapeutic genes in angiogenic vessels. 6 Focus has been placed on the improvement of delivery vehicles, both viral and non-viral, as well as on the isolation of endothelial cell (EC)-specific promoters from genes such as vascular endothelial growth factor receptors (VEGF-R1 7 /VEGF-R2 8 ), intercellular adhesion molecule-2 (ICAM-2), 7, 9, 10 von Willebrand factor 7 and preproendothelin 1 (PPE). 11, 12 However, except for the PPE promoter, these promoters are not specific for angiogenic blood vessels. Unlike these pan-EC promoters, the mouse activin receptor-like kinase 1 (Alk1; Acvrl1) promoter induces transgene expression specifically in ECs of newly forming and remodeling arteries that feed ischemic lesions and developing tumors.
ALK1 is one of the type I receptors for the transforming growth factor b (TGF-b) superfamily ligands. We have shown using Alk1 +/lacZ reporter knock-in mice that Alk1 gene expression is detected in a transient manner in the arteries feeding ischemic tissues. 13 This gene, with its unique expression pattern, might be exploited to aid in the delivery of a therapeutic peptide to downstream ischemic tissues. To this end, we began characterizing the Alk1 gene regulatory region using a transgenic mouse system and have isolated a 9.2-kb Alk1 regulatory fragment. 14 The transgenic mouse line with this 9.2-kb fragment, Tg(Alk1-lacZ), virtually recapitulated the reporter gene expression pattern observed in Alk1 +/lacZ mice. The viral gene transfer vectors used in gene therapy, however, have limited payload capacities, and the 9.2-kb fragment is too large to be used in most of the vectors. 15 In this study, we generated a shortened 4.8-kb Alk1PIB (Promoter-Intron 2B) regulatory fragment based on the evolutionarily conserved region (ECR) analysis. 16 This fragment allowed the development of transgenic mouse lines with transgene expression targeted to the feeding arteries. In addition, a recombinant adenovirus with the Alk1PIB fragment induced transgene expression in primary culture arterial ECs. This 4.8-kb fragment may be an invaluable tool for the development of gene therapies to target arteries feeding ischemic tissues.
Results
ECRs in intergenic and intron sequences are most likely to have functional importance, especially in the regulation of gene expression. 16 On the basis of our earlier transgenic mouse experiments and ECR analysis between the mouse and human ALK1 genes (Figure 1a ), 14 we hypothesized that the conserved regions within the 9.2-kb pXh4.5-in2 Alk1 regulatory fragment are sufficient to target transgene in a manner seen for expression of endogenous Alk1. In order to test this hypothesis, we created a shortened regulatory fragment, Alk1PIB, by eliminating non-conserved sequences and connecting the conserved promoter (Prom) and the 3 0 half of intron 2 (Int2B). The 4.8-kb Alk1PIB fragment was ligated to a lacZ reporter cassette to generate a transgenic construct, Alk1PIB-lacZ (Figure 1b) , and three transgenic mouse lines, Tg(Alk1PIB-lacZ)A8, E16 and F8 (TgA8, TgE16, TgF8 hereafter), were established.
The targeting ability of the Alk1PIB fragment was visualized by X-gal staining. On application of X-gal staining solution, the lacZ gene product, b-galactosidase, hydrolyzes X-gal to produce an insoluble blue dye. Hence, blue staining in cells indicates active transcription from the Alk1PIB regulatory fragment. Analyses of the three transgenic mouse lines showed that the Alk1PIB activities during the postnatal stages were largely consistent among the three lines, with some ectopic expression found only in the TgA8 line. This ectopic expression was observed in cerebellar Perkinje neurons (strong expression), a small number of skeletal muscle fibers (moderate expression), cardiac muscle cells (weak expression) and some other organs (very weak expression). Overall, TgA8 line had the strongest staining intensities among the three lines. Unless otherwise indicated, expression patterns commonly observed in all three lines are described below.
The overall regulatory activities of the Alk1PIB fragment during postnatal growth stages and in adults were blood vessel-specific and similar to that seen for the endogenous Alk1 gene (Figure 2 ). The transgene showed high expression in the lungs throughout postnatal life and no expression in the liver (data not shown). In other organs, expression was evident in the arteries and some and Tg(Alk1-lacZ) mice (Figures 2f and h ).
Histological analysis indicated that expression of the transgene in young animals was localized in vascular ECs and smooth muscle cells (SMCs) in all of the organs examined. Faint expression was observed in some venous ECs and SMCs, but most was observed in arterial and capillary ECs (Figure 2j) , which was consistent with expression of endogenous Alk1. Although endogenous Alk1 was seldom detected in SMCs, the Alk1PIB fragment was active in some vascular SMCs. Both positive and negative SMCs were found in random order in a section of an artery (Figure 2k ). In adults, transgene expression was virtually diminished in all organs except the lungs. A more thorough investigation identified a small number of positively stained arteries in various organs, most often in the brain, and that staining was localized in arterial ECs and SMCs (Figure 2l ).
Alk1PIB targeting activity was next examined in angiogenic lesions in adults. During wound healing, the Alk1PIB fragment transiently induced transgene expression in the arteries feeding wound lesions ( Figure 3 ). Full-thickness skin wounds were created on mouse skin, and the skin samples were collected at several time points for each of the mouse lines. As in Alk1 +/lacZ mice (Figure 3c ), transient expression was detected in blood vessels from the samples on day 5 (TgA8, Figure 3a) ; days 8 and 10 (TgE16); and days 3, 5 and 8 (TgF8, Figure 3b ). The staining diminished once wounds were completely healed. Expression was limited to arteries, where expression was seen in both arterial ECs and SMCs (Figures 3d-g ).
To observe Alk1PIB activity in another angiogenic model, mouse B16 melanoma cells were injected into TgA8 mice to create subcutaneous tumors. Endogenous Alk1 has been shown to be activated in newly forming and feeding arteries in a teratoma model. 13 In TgA8 mice, subcutaneous B16 tumors were rarely palpable on day 7 (n ¼ 3; 0-1.5 mm 3 ). On day 14, many of the injection sites had detectable tumors (n ¼ 3; 64-648 mm 3 ); however, Alk1PIB activity was detected only in a few feeding arteries, even in the mouse with the largest tumor at this stage ( Figure 4a ). As tumor sizes increased on days 21 (n ¼ 3; 543-955 mm 3 ) and 28 (n ¼ 3; 939-2475 mm 3 ), Alk1PIB was clearly active in the feeding arteries of these larger tumors (Figures 4b and c) . Histological sections of B16 tumors showed X-gal-stained arteries in connective tissues encapsulating tumors, but none were identified inside the tumors (data not shown).
Lastly, as most of the delivery vectors for gene therapy are viral, we investigated the Alk1PIB regulatory activity using a recombinant adenovirus system. Recombinant adenoviruses carrying a reporter transgene, ZsGreen1-DR green fluorescent protein (ZsG), were generated with four regulatory fragments, including Alk1PIB, human ICAM2 (hICAM2), human VEGF-R1 (fms-like tyrosine kinase 1, hFLT1) and cytomegalovirus (CMV) early promoter. The viruses were used to infect human iliac arterial endothelial cells (HIAECs) ( Figure 5 ) and fibroblasts (data not shown). No detectable ZsG expression was observed in fibroblasts with Ad-Alk1PIB-ZsG, Ad-hICAM2-ZsG or Ad-hFLT1-ZsG viruses, illustrating Shortened ALK1 regulatory fragment X Li et al their EC specificity. Ad-CMV-ZsG virus induced ZsG expression in most of the HIAECs; however, the expression levels varied from cell to cell, suggesting infection heterogeneity (Figures 5e and f) . To quantify the transgene expression, the number of ZsG-expressing cells and total number of cells in the digital images were counted to determine the proportion of ZsG-expressing cells. The Alk1PIB induced ZsG expression in 17.0 ± 1.9% of HIAECs, which was higher than hFLT1 (2.3±0.3%) and lower than hICAM2 (28.2 ± 1.2%) (Figure 5g ). These results indicate that the Alk1PIB fragment can be used in an adenovirus vector.
Discussion
On the basis of the ECR analysis, a shortened Alk1 gene fragment, 4.8-kb Alk1PIB, was constructed and shown to cause an expression pattern similar to that of endogenous Alk1. For instance, expression was seen in arteries and some capillaries in mice that were newborn and 2-3 weeks of age. Transcriptional activity then became virtually absent in all of the adult organs tested except for the lungs, but expression could be induced in the newly forming and remodeling arteries associated with wound healing and tumor lesions. In addition, the Alk1PIB fragment was successfully used in a recombinant adenovirus vector to induce transgene expression in cultured arterial ECs, indicating the potential for future viral gene therapy application.
Differences from the endogenous Alk1 expression pattern were seen in the arterial SMCs and the overall expression level. Alk1 expression in SMCs has been seen only in a limited number of arteries at 2-3 weeks of age, 13 whereas the Alk1PIB fragment drove transgene expression in arterial SMCs at all stages examined. This Shortened ALK1 regulatory fragment X Li et al additional expression may be because of the loss of an SMC-specific silencer element located in the deleted regions. Alternatively, reduction in the distance between the Prom and Int2B regions may have caused difficulty in forming a loop structure between these two regions, which may have led to SMC expression. Indeed, in the hemoglobin genes, distant enhancer and promoter regions have been shown to form a loop structure that is necessary for maximal transcriptional activity. 17 The Alk1 induction in newly forming and remodeling arteries is unique, and it is intriguing to investigate the stimulus that induces this expression. By inducing arterial wall remodeling using a mesenteric artery ligation model in the Alk1 +/lacZ mice, which induces shear stress-mediated arterial wall remodeling, we have hypothesized that endogenous Alk1 induction may relate to changes in blood flow (shear stress) within arteries. 13 In order to test whether shear stress induces ALK1 expression, we applied physiological and higher levels of shear stress to HIAECs; however, ALK1 induction was not detected (data not shown). This suggests that simple shear stress may not be the factor that induces ALK1 expression. An alternative approach to understand tissue regulation of ALK1 induction would be to characterize its DNA regulatory elements. Using ECR analysis with multiple genomes and the recombinant adenovirus reporter system, we are currently carrying out a detailed regulatory element analysis in order to identify essential cis-regulatory elements for Alk1 expression.
The Alk1PIB fragment has potential use in experimental and gene therapy applications across several research areas. Targeting gene delivery to angiogenic lesion would be beneficial for many disorders. Until now, the PPE promoter 11, 12 was the only angiogenic vasculature-specific promoter fragment available. The Alk1PIB fragment has an advantage over the PPE promoter, as it is expressed only in the arteries feeding ischemic lesions. 
Shortened ALK1 regulatory fragment X Li et al
This activity may be used to provide targeted secretion of therapeutic proteins into the blood stream, which would be transported directly into the adjacent ischemic lesion. Alternatively, the feeding arteries may be destroyed to terminate blood supply by expressing cytotoxic proteins. The 4.8 kb fragment is small enough to use in many viral vectors, and future engineering, based on detailed ECR analysis, may enable us to enhance its induction capacity, eliminate pulmonary capillary expression, and further shorten the fragment.
Materials and methods

ECR analyses and Tg(Alk1PIB-lacZ) mouse generation
Alignments of the mouse Alk1 gene and regulatory fragments to human genomic sequences were obtained from the ECR Browser 16 (http://ecrbrowser.dcode.org) by searching with the ALK1 gene symbol 'ACVRL1.' The ECR Browser shows pre-computed alignments of publicly available genome sequences and highlights ECRs. The alignment presented in Figure 1a was created with mouse July 2007 (mm9) genome assembly and human March 2006 (hg18) assembly.
On the basis of the ECR analysis, the following conserved DNA fragments were isolated from mouse Alk1 genomic DNA: the promoter region (Prom), which is a 2.6 kb EcoRI-EcoRI fragment covering 1.7 kb of the promoter, exon 1, intron 1, exon 2, and a part of intron 2, as well as the 3 0 region of intron 2 (Int2B), which is a 2.2 kb BglII-BglII fragment covering 2 kb of intron 2 and a part of exon 3 (0.2 kb) upstream of the translation start site. The Prom and Int2B fragments were ligated to create the 4.8 kb Alk1PIB regulatory fragment. The Alk1PIB-lacZ construct was created by subcloning the Alk1PIB fragment upstream of the pSIB reporter cassette, 14 which contains the Simian virus 40 (SV40) splice donor/ acceptor sites (SD/SA), internal ribosome entry site (IRES), and the lacZ reporter gene (Figure 1b) . Institutional Animal Care and Use Committee. Founder lines were screened by genomic Southern blot using the lacZ gene as a probe. Ten founder lines were further examined for transgene expression by X-gal staining of organs at various ages. Consequently, three new mouse lines, TgA8, E16, and F8, were established. The transgene-positive animals were identified by X-gal staining of tail tips at two to 3-weeks old and/or by polymerase chain reaction (PCR) of tail genomic DNA using forward primer in Alk1 intron 2 sequence, agtgaaccaggacttcccttgcag and reverse primer in SD/SA sequence, cgggtacaattccgcagcttttag.
Wound healing and subcutaneous tumor models
The wound healing model was created by placing three 4 mm-diameter full-thickness excisional wounds on the mid-dorsum using a biopsy punch as described earlier. 13 All three mouse lines were tested. The wounds were left unsutured, and the areas had completely recovered after 14 days in most cases. The mice were killed on days 3, 5, 8, 10, and 14 after wounding, and the skins were processed for X-gal staining and photography.
Mouse B16-F10 melanoma cells were purchased from the American Type Cell Culture (ATCC, Manassas, VA, USA) and propagated as recommended. One million cells were injected subcutaneously into 8-12-weekold TgA8 mice. Tumor size was measured as 1/ 2 Â length Â width 2 (length 4width). Only a few tiny tumors were palpable at the injection sites 7 days after injection (day 7). The tumor and surrounding skin samples were prepared on days 14, 21, and 28 (n ¼ 3 each). At each time point, mice harboring relatively large tumors were selected from the remaining animals to analyze for active angiogenesis in the lesions. The samples were processed for X-gal staining and photographed.
X-gal staining, clearing, histology, and immunohistochemistry
The following mouse organs were examined for transgene expression at birth (newborn), at 2 to 3 weeks, and at 12-16 weeks (adult): brain, heart, lungs, liver, mesenteric membrane, abdominal skeletal muscles, skin, and aorta. In addition, the kidneys, adrenal glands, ovary, and uterus from adult mice were examined. Tissue sample preparation, X-gal staining, and immunohistochemistry were carried out as described earlier. 13 Briefly, tissue samples were dissected in 1-2 mm slices to facilitate penetration of the X-gal solution and were stained overnight. The stained samples were then photographed and fixed with 10% formalin, 4% paraformaldehyde, or zinc fixative, followed by embedding in paraffin for histology or cleared with 1:1 mixture of benzyl alcohol and benzyl benzoate (both from SigmaAldrich, St Louis, MO, USA) for whole mount imaging. Once cleared, the tissues become transparent, and blue staining at any depth could be observed. After a published protocol, 18 some of the tissues were embedded in OCT compound, frozen-sectioned, and then X-gal stained for observation as well. Anti-platelet endothelial cell adhesion molecule 1 (PECAM, clone: Mec13.3; BD Biosciences, San Jose, CA, USA) and anti-smooth muscle a-actin (SMA, clone: 1A4; Sigma-Aldrich) antibodies were used to identify ECs and SMCs, respectively.
Tissues from littermate wild-type C57 mice were used as a negative control.
Recombinant adenovirus production
Promoter fragments of the CMV, the human VEGF-R1 (hFLT1) gene, 7 and the hICAM2 gene, 9,10 as well as the Alk1PIB fragment were first individually subcloned into pENTR vectors (Invitrogen, Carlsbad, CA, USA), followed by addition of a ZsGreen1-DR (ZsG) green fluorescent protein gene excised from pZsGreen1-DR vector (Clontech Laboratories, Inc., Mountain View, CA, USA). The CMV-ZsG, hFLT1-ZsG, hICAM2-ZsG, and ALK1PIB-ZsG sequences in the pENTR vector were transferred to the destination vector pAd/PL-DEST (Invitrogen), with the Gateway Clonase II Enzyme Mix (Invitrogen) to create pAd-CMV-ZsG, pAd-hFLT1-ZsG, pAd-hICAM2-ZsG, and pAd-Alk1PIB-ZsG constructs, respectively. They were then transfected into 293A cells (Invitrogen) using ProFection Mammalian Transfection Systems (Promega, Madison, WI, USA), and virus particles were produced. A large-scale amplification, cesium chloride (CsCl) purification, and titration of the viruses were carried out by Vector Biolabs Inc. (Philadelphia, PA, USA).
Promoter activity assay in HIAECs and fibroblasts
Primary HIAECs (Lonza Walkersville, Inc., Walkersville, MD, USA) were propagated according to the manufacturer's recommendation. Telomerase-induced immortalized fibroblasts 19 (a kind gift from Dr William Rainey) were propagated in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum. For adenovirus infection, HIAECs at passage six and fibroblasts were trypsinized and plated into 24-well plates at 5 Â 10 4 cells per well density, and the cells were infected with 5 Â 10 7 plaque forming unit (pfu) recombinant adenoviruses on the following day. A media change was carried out 16 h after infection. The cells were then incubated in complete media for 4 days, and a medium change was carried out every 2 days. The numbers of ZsG-expressing cells was counted as follows: three fluorescence images and their corresponding phasecontrast images, one from the center and two from the peripheral of the well, were taken from each well using fluorescence microscopy with an Â 10 objective lens and 101 ms exposure time, and the numbers of the cells in the images were then counted. As Ad-CMV-ZsG virus expressed ZsG protein very intensely, 3 ms exposure images were used for counting instead. Even with 312 ms exposure, ZsG expression was not found in the fibroblasts infected with Ad-Alk1PIB-ZsG, Ad-hICAM2-ZsG, and Ad-hFLT1-ZsG viruses. On average, a total of 1333±115.2 (s.d.) HIAECs (n ¼ 12 wells) were found in the three images taken from a single well. Each virus was infected to three independent wells, and the average number of positive cells and standard error were calculated. The infection was repeated at least three times, and representative data are shown in Figure 5 .
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